Advanced search
Publication Cover
mAbs Volume 14, 2022 - Issue 1
Submit an article Journal homepage
3,304
Views
4
CrossRef citations to date
0
Altmetric
Report

Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)

James Sweet-JonesInstitute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UKView further author information
,
Maham AhmadInstitute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UKView further author information
&
Andrew C.R. MartinInstitute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2835-2572View further author information
ORCID Icon
Article: 2101183 | Received 09 May 2022, Accepted 08 Jul 2022, Published online: 15 Jul 2022

References

  • Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.
  • Adams R, Maroof A, Baker T, G LAD, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01894.
  • Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130.
  • Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–7.
  • Wilke AC, Gökbuget N. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf. 2017;16:1191–202.
  • Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (Removab). J Cancer. 2011;2:309–16.
  • Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, Negrier C, Callaghan MU, Levy GG. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost. 2021;121:351–60.
  • Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983;305:537–40.
  • Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–47.
  • Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2 Pt A):95–106. doi:10.1016/j.molimm.2015.01.003.
  • Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212.
  • Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 1999;453:164–68.
  • Ridgway JBB, Presta LG, Carter PJ. ‘knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9:617–21.
  • Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, B NS, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285:19637–46.
  • Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868–76.
  • Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK. Advances in antibody-drug conjugates: a new era of targeted cancer therapy. Drug Discov Today. 2017;22:1547–56.
  • Szijj P, Chudasama V. The renaissance of chemically generated bispecific antibodies. Nat Rev Chem. 2021;5:78–92.
  • Weininger D. SMILES, a chemical language and information system. 1. introduction to methodology and encoding rules. J Chem Inf Comput Sci. 1988;28:31–36.
  • Zhang T, Li H, Xi H, Stanton RV, Rotstein SH. HELM: a hierarchical notation language for complex biomolecule structure representation. J Chem Inf Model. 2012;52:2796–806.
  • Dal Corso A, Pignataro L, Belvisi L, Gennari C. Innovative linker strategies for tumor-targeted drug conjugates. Chem Eur J. 2019;25:14740–57.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.